Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial

[1]  G. Schuler,et al.  Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI): study protocol for a randomized controlled trial , 2013, Trials.

[2]  P. Sørensen,et al.  Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial , 2011, The Lancet Neurology.

[3]  M. Sahraian,et al.  Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial , 2010, Multiple sclerosis.

[4]  R. Marrie,et al.  Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis , 2010, Neurology.

[5]  G. Tedeschi,et al.  Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy , 2010, Multiple sclerosis.

[6]  C. Kamm,et al.  SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology , 2009, Trials.

[7]  P. Calabresi,et al.  Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a , 2009, Neurology.

[8]  S. Ludwin,et al.  Statin therapy inhibits remyelination in the central nervous system. , 2009, The American journal of pathology.

[9]  R. Marrie,et al.  Comorbidity delays diagnosis and increases disability at diagnosis in MS , 2009, Neurology.

[10]  H. Althaus,et al.  Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo , 2008, The Journal of Neuroscience.

[11]  G. Schroth,et al.  A Novel Method for Analyzing DSCE-Images With an Application to Tumor Grading , 2008, Investigative radiology.

[12]  Isak Prohovnik,et al.  Cross-validation of brain segmentation by SPM5 and SIENAX , 2008, Psychiatry Research: Neuroimaging.

[13]  A. Reder,et al.  Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis , 2008, Neurology.

[14]  F. Paul,et al.  Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis , 2008, PloS one.

[15]  I. Singh,et al.  Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. , 2008, Future neurology.

[16]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[17]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[18]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[19]  H. Hartung,et al.  Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. , 2004, Archives of neurology.

[20]  V. Durkalski,et al.  Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.

[21]  S. Youssef,et al.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.

[22]  V. Gebski,et al.  Randomisation in clinical trials , 2002, The Medical journal of Australia.

[23]  F. Fazekas,et al.  Statins as immunomodulators: Comparison with interferon-&bgr;1b in MS , 2002, Neurology.

[24]  P. Carrieri,et al.  Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory , 2002, Journal of neurology, neurosurgery, and psychiatry.

[25]  D. Li,et al.  Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. , 2001, Neurology.

[26]  I. Singh,et al.  Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis , 2001, Journal of neuroscience research.

[27]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[28]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[29]  I. Singh,et al.  Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin , 1999, Neuroscience Letters.

[30]  A. Gatherer,et al.  Sarcoma of the Larynx , 1958, The Journal of Laryngology & Otology.

[31]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[32]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[33]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .

[34]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[35]  Fifty-sixth Report.  WHO Expert Committee on biological standardization. , 2007, World Health Organization technical report series.

[36]  J. Abraham.  The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[37]  M. Arca.  Atorvastatin , 2012, Drugs.

[38]  F. Bernini,et al.  Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin , 2004, Cardiovascular Drugs and Therapy.

[39]  Paty Dw,et al.  Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. , 2001, Neurology.

[40]  J. Carter,et al.  The immunopathology of multiple sclerosis , 1991 .